Brincidofovir Patent Expiration
Brincidofovir is Used for treating human smallpox disease. It was first introduced by Emergent Biodefense Operations Lansing Llc
Brincidofovir Patents
Given below is the list of patents protecting Brincidofovir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tembexa | US10112909 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US10487061 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US8962829 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US9371344 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | Oct 10, 2034 | Emergent Biodefense |
| Tembexa | US9303051 | Phosphonate ester derivatives and methods of synthesis thereof | Aug 31, 2031 | Emergent Biodefense |
| Tembexa | US9303051 | Phosphonate ester derivatives and methods of synthesis thereof | Aug 31, 2031 | Emergent Biodefense |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Brincidofovir's patents.
Latest Legal Activities on Brincidofovir's Patents
Given below is the list recent legal activities going on the following patents of Brincidofovir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9303051 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9303051 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9371344 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2023 | US9303051 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 May, 2023 | US10487061 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US10112909 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US9371344 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US8962829 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US9303051 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 08 Feb, 2023 | US10487061 |
Brincidofovir's Family Patents
